Letizia Mazzini, Maurizio Gelati, Daniela Celeste Profico, Gianni Sorarù, Daniela Ferrari, Massimiliano Copetti, Gianmarco Muzi, Claudia Ricciolini, Sandro Carletti, Cesare Giorgi, Cristina Spera, Domenico Frondizi, Stefano Masiero, Alessandro Stecco, Carlo Cisari, Enrica Bersano, Fabiola De Marchi, Maria Francesca Sarnelli, Giorgia Querin, Roberto Cantello, Francesco Petruzzelli, Annamaria Maglione, Cristina Zalfa, Elena Binda, Alberto Visioli, Domenico Trombetta, Barbara Torres, Laura Bernardini, Alessandra Gaiani, Maurilio Massara, Silvia Paolucci, Nicholas M Boulis, Angelo L Vescovi
The main objective of this phase I trial was to assess the feasibility and safety of microtransplanting human neural stem cell (hNSC) lines into the spinal cord of patients with amyotrophic lateral sclerosis (ALS). Eighteen patients with a definite diagnosis of ALS received microinjections of hNSCs into the gray matter tracts of the lumbar or cervical spinal cord. Patients were monitored before and after transplantation by clinical, psychological, neuroradiological, and neurophysiological assessment. For up to 60 months after surgery, none of the patients manifested severe adverse effects or increased disease progression because of the treatment...
September 2019: Stem Cells Translational Medicine